| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | RVLP | Ordinary Shares | Sale | -$432K | -9.36M | -49.12% | $0.05 | 9.7M | Oct 19, 2023 | By Self as indirect owner of Altchem Limited | F1, F2 |
| transaction | RVLP | Ordinary Shares | Sale | -$148K | -4.76M | -49.06% | $0.03 | 4.94M | Oct 20, 2023 | By Self as indirect owner of Altchem Limited | F2, F3 |
Harsaul Foundation is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.
| Id | Content |
|---|---|
| F1 | The price reported in Column 4 is the average execution price. These shares were sold in multiple transactions at prices ranging from $0.0400 to $0.0580, inclusive. The reporting person undertakes to provide RVL Pharmaceuticals plc, any security holder of RVL Pharmaceuticals plc or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F2 | Represents shares of the Issuer held by Altchem Limited. Harsaul Foundation is the indirect owner of Altchem Limited. As a result, Harsaul Foundation may be deemed to share voting and investment power with respect to the shares held by Altchem Limited. |
| F3 | The price reported in Column 4 is the average execution price. These shares were sold in multiple transactions at prices ranging from $0.0300 to $0.0373, inclusive. The reporting person undertakes to provide RVL Pharmaceuticals plc, any security holder of RVL Pharmaceuticals plc or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |